GE Healthcare acquired Biosafe Group, which supplies integrated cell bioprocessing systems for the cell therapy and regenerative medicine industry, for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions, and services for its cell therapy customers and expands GE’s technology reach to a number of new cell and therapy types, according to Kieran Murphy, CEO Life Sciences, GE Healthcare.
Biosafe, headquartered in the Lake Geneva region in Switzerland, markets products with closed fluid pathways, built-in traceability, and single-use consumables.
Murphy said: “GE is building a world-class set of tools, technologies, and services for cell and gene therapy and Biosafe’s expertise and innovative systems will strongly enhance our customer offering. GE and Biosafe share a vision of an integrated approach to helping customers optimize every stage of their process to reduce production risks dramatically and increase access to these remarkable new medicines.”
“Together with GE we will have the combination of biological, engineering, and industrial capabilities to help accelerate the fields of cell therapy and cellular immunotherapy into the mainstream, benefitting patients globally, and bringing the vision of personalized medicine to reality,” added Claude Fell, founder and chairman of Biosafe.